Anti-Amyloid Therapies for Alzheimer's Disease: Progress, Pitfalls, and the Path Ahead. — Anti-amyloid monoclonal antibodies have finally achieved their translational breakthrough after many years of unmet expectations. The FDA granted traditional approval to lecanemab in July 2023, and the European Medicines...

Evidence span

Anti-Amyloid Therapies for Alzheimer's Disease: Progress, Pitfalls, and the Path Ahead. — Anti-amyloid monoclonal antibodies have finally achieved their translational breakthrough after many years of unmet expectations. The FDA granted traditional approval to lecanemab in July 2023, and the European Medicines...

From Papaliagkas V 2025, International journal of molecular sciences

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Humans; Alzheimer Disease; Apolipoproteins E; Patient Selection; Risk Management — International journal of molecular sciences 2025

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required